- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
ANDA Litigation Settlements
Winter 2013
|
Case Name |
Drug |
Patent |
Publicly Available Terms |
|
Purdue Pharma LP v. Impax Labs. Inc, 13-0763 (S.D.N.Y.) |
OxyContin®(oxycodone hydrochloride extended-release tablets) |
8,114,383 8,309,060 |
Impax agrees not to market or sell its ANDA product and will not challenge the validity of Purdue Pharma’s patents until an unspecified date; Impax agrees to drop any potential antitrust or other claim against Purdue Pharma. |
|
Hospira Inc. v. Sandoz Inc. (Fed. Cir.) |
Precedex®(dexmedetomidine hydrochloride injection) |
4,910,214 6,716,867 |
Sandoz may launch its ANDA product on December 26, 2014, unless certain conditions relating to launch, if triggered, lead to an earlier Sandoz market entry date |
|
Novartis AG v. Accord Healthcare Inc., 13-1013 (D.D.C.) |
Myfortic®(mycophenolic acid) |
6,025,391 6,172,107 6,306,900 |
N/A |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.